[go: up one dir, main page]

DK3452484T3 - Visse protein-kinase-inhibitorer - Google Patents

Visse protein-kinase-inhibitorer Download PDF

Info

Publication number
DK3452484T3
DK3452484T3 DK17795490.6T DK17795490T DK3452484T3 DK 3452484 T3 DK3452484 T3 DK 3452484T3 DK 17795490 T DK17795490 T DK 17795490T DK 3452484 T3 DK3452484 T3 DK 3452484T3
Authority
DK
Denmark
Prior art keywords
protein kinase
kinase inhibitors
certain protein
certain
inhibitors
Prior art date
Application number
DK17795490.6T
Other languages
English (en)
Inventor
Tongshuang Li
Weibo Wang
Xingdong Zhao
Zhifang Chen
Rui Tan
Ling Chen
Xianlong Wang
Lijun Yang
Zuwen Zhou
Yanxin Liu
Min Lin
Jing Sun
Original Assignee
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Pharmaceuticals Ltd filed Critical Fochon Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3452484T3 publication Critical patent/DK3452484T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DK17795490.6T 2016-05-07 2017-05-05 Visse protein-kinase-inhibitorer DK3452484T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333165P 2016-05-07 2016-05-07
PCT/CN2017/083162 WO2017193872A1 (en) 2016-05-07 2017-05-05 Certain protein kinase inhibitors

Publications (1)

Publication Number Publication Date
DK3452484T3 true DK3452484T3 (da) 2023-09-25

Family

ID=60266275

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17795490.6T DK3452484T3 (da) 2016-05-07 2017-05-05 Visse protein-kinase-inhibitorer

Country Status (14)

Country Link
US (1) US10835535B2 (da)
EP (1) EP3452484B1 (da)
JP (1) JP6927548B2 (da)
KR (1) KR102374033B1 (da)
CN (1) CN109153686B (da)
AU (1) AU2017262155B2 (da)
CA (1) CA3023460A1 (da)
DK (1) DK3452484T3 (da)
ES (1) ES2954148T3 (da)
MX (1) MX387648B (da)
RU (1) RU2738837C2 (da)
TW (1) TWI752026B (da)
WO (1) WO2017193872A1 (da)
ZA (1) ZA201808238B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN116836177A (zh) * 2022-09-28 2023-10-03 锦州奥鸿药业有限责任公司 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途
WO2025085360A1 (en) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DK1019385T3 (da) 1995-09-15 2004-05-24 Upjohn Co Aminoaryloxazolidinon-N-oxider
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
PL1768967T3 (pl) 2004-07-20 2009-09-30 Symed Labs Ltd Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
CA2686545C (en) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
DE102007038251A1 (de) 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
PL2215094T3 (pl) * 2007-11-15 2016-09-30 Związki heterocykliczne zawierające n
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
US10087195B2 (en) * 2014-05-28 2018-10-02 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Also Published As

Publication number Publication date
ES2954148T3 (es) 2023-11-20
RU2018143284A (ru) 2020-06-08
CN109153686A (zh) 2019-01-04
EP3452484B1 (en) 2023-07-05
CN109153686B (zh) 2021-04-30
JP6927548B2 (ja) 2021-09-01
RU2738837C2 (ru) 2020-12-17
AU2017262155B2 (en) 2021-03-11
US20190209566A1 (en) 2019-07-11
CA3023460A1 (en) 2017-11-16
JP2019516790A (ja) 2019-06-20
EP3452484A1 (en) 2019-03-13
WO2017193872A1 (en) 2017-11-16
BR112018072699A2 (pt) 2019-02-19
US10835535B2 (en) 2020-11-17
AU2017262155A1 (en) 2018-12-06
TW201805290A (zh) 2018-02-16
ZA201808238B (en) 2022-10-26
MX387648B (es) 2025-03-18
KR102374033B1 (ko) 2022-03-14
RU2018143284A3 (da) 2020-07-31
TWI752026B (zh) 2022-01-11
MX2018013573A (es) 2019-08-01
KR20190025545A (ko) 2019-03-11
EP3452484A4 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
IL263586A (en) Inhibitors of the menin-mll interaction
IL269196A (en) Novel inhibitors
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3303334T3 (da) Tyrosinkinasehæmmere
DK3365334T3 (da) Benzolactamforbindelser som proteinkinaseinhibitorer
DK3442972T3 (da) Bromdomænehæmmere
HUE057801T2 (hu) Aminotriazolopiridinek mint kináz inhibitorok
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
DK3571192T3 (da) Jak1-selektive inhibitorer
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
DK3288931T4 (da) Visse proteinkinaseinhibitorer
IL294381A (en) Pcna inhibitors
MA42242A (fr) Inhibiteurs de la tyrosine kinase
MA44006A (fr) Inhibiteur pde1
DK3341379T3 (da) EZH2-hæmmere
HUE058292T2 (hu) Aminoimidazopiridazinok mint kináz inhibitorok
EP3804707A4 (en) KINASE INHIBITOR
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3555092A4 (en) PROTEIN KINASE INHIBITORS
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3600301A4 (en) KDM4 INHIBITORS
ZA201808238B (en) Certain protein kinase inhibitors
EP3454852A4 (en) PHOSPHOTIDYLINOSITOL 3-KINASES INHIBITORS
MA44607A (fr) Inhibiteurs de kinase
LT3194407T (lt) Makrocikliniai rip2 kinazės inhibitoriai